Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MannKind

MannKind Expands Executive Leadership Team
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
From MannKind
Via GlobeNewswire
Tickers MNKD
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Present at 2024 UBS Healthcare Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Present at Upcoming Conferences
From MannKind
Via GlobeNewswire
Tickers MNKD
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
Tickers MNKD
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Repays Certain Debt Obligations
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces CFO Transition
From MannKind
Via GlobeNewswire
Tickers MNKD
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Announces Participation at Upcoming Conferences
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
Tickers MNKD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.